MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics (Nasdaq: MGNX), a biopharmaceutical company specializing in cancer treatment through monoclonal antibody-based therapeutics, has announced its participation in three major investor conferences in March 2025:
- TD Cowen 45th Annual Healthcare Conference in Boston - CEO Scott Koenig will lead a fireside chat on March 5 at 10:30am ET
- Leerink Partners 2025 Global Healthcare Conference in Miami - Fireside chat scheduled for March 11 at 11:20am ET
- Barclays 27th Global Healthcare Conference in Miami - Presentation set for March 12 at 2:00pm ET
The company will conduct one-on-one meetings at all events. Webcasts will be available on MacroGenics' website under the Investor Relations section, with 30-day replay access.
MacroGenics (Nasdaq: MGNX), una compagnia biofarmaceutica specializzata nel trattamento del cancro attraverso terapie a base di anticorpi monoclonali, ha annunciato la sua partecipazione a tre importanti conferenze per investitori a marzo 2025:
- TD Cowen 45a Conferenza Annuale sulla Sanità a Boston - Il CEO Scott Koenig condurrà una chiacchierata informale il 5 marzo alle 10:30 ET
- Leerink Partners 2025 Conferenza Globale sulla Sanità a Miami - Chiacchierata informale programmata per l'11 marzo alle 11:20 ET
- Barclays 27a Conferenza Globale sulla Sanità a Miami - Presentazione fissata per il 12 marzo alle 14:00 ET
La compagnia condurrà incontri individuali in tutti gli eventi. Le trasmissioni in diretta saranno disponibili sul sito web di MacroGenics nella sezione Relazioni con gli Investitori, con accesso alla riproduzione per 30 giorni.
MacroGenics (Nasdaq: MGNX), una compañía biofarmacéutica especializada en el tratamiento del cáncer mediante terapias basadas en anticuerpos monoclonales, ha anunciado su participación en tres importantes conferencias de inversores en marzo de 2025:
- 45ª Conferencia Anual de Salud de TD Cowen en Boston - El CEO Scott Koenig liderará una charla informal el 5 de marzo a las 10:30 a.m. ET
- Conferencia Global de Salud 2025 de Leerink Partners en Miami - Charla informal programada para el 11 de marzo a las 11:20 a.m. ET
- 27ª Conferencia Global de Salud de Barclays en Miami - Presentación programada para el 12 de marzo a las 2:00 p.m. ET
La compañía llevará a cabo reuniones uno a uno en todos los eventos. Las transmisiones estarán disponibles en el sitio web de MacroGenics en la sección de Relaciones con Inversores, con acceso a la repetición durante 30 días.
MacroGenics (Nasdaq: MGNX), 단클론 항체 기반 치료법을 통해 암 치료를 전문으로 하는 생명공학 회사는 2025년 3월에 열리는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다:
- TD Cowen 제45회 연례 헬스케어 회의 - CEO Scott Koenig이 3월 5일 오전 10시 30분 ET에 대담을 이끌 예정입니다.
- Leerink Partners 2025 글로벌 헬스케어 회의 - 3월 11일 오전 11시 20분 ET에 대담이 예정되어 있습니다.
- Barclays 제27회 글로벌 헬스케어 회의 - 3월 12일 오후 2시 ET에 발표가 예정되어 있습니다.
회사는 모든 행사에서 일대일 미팅을 진행합니다. 웹캐스트는 MacroGenics 웹사이트의 투자자 관계 섹션에서 제공되며, 30일 동안 다시 볼 수 있습니다.
MacroGenics (Nasdaq: MGNX), une entreprise biopharmaceutique spécialisée dans le traitement du cancer par des thérapies à base d'anticorps monoclonaux, a annoncé sa participation à trois grandes conférences pour investisseurs en mars 2025 :
- 45e Conférence Annuelle de la Santé de TD Cowen à Boston - Le PDG Scott Koenig animera une discussion informelle le 5 mars à 10h30 ET
- Conférence Mondiale de la Santé 2025 de Leerink Partners à Miami - Discussion informelle prévue pour le 11 mars à 11h20 ET
- 27e Conférence Mondiale de la Santé de Barclays à Miami - Présentation prévue pour le 12 mars à 14h00 ET
L'entreprise organisera des réunions individuelles lors de tous les événements. Les webdiffusions seront disponibles sur le site Web de MacroGenics dans la section Relations avec les Investisseurs, avec un accès à la rediffusion pendant 30 jours.
MacroGenics (Nasdaq: MGNX), ein biopharmazeutisches Unternehmen, das sich auf die Krebsbehandlung mit monoklonalen Antikörpertherapien spezialisiert hat, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im März 2025 angekündigt:
- 45. TD Cowen Jahrestagung zur Gesundheitsversorgung in Boston - CEO Scott Koenig wird am 5. März um 10:30 Uhr ET ein Gespräch führen
- Leerink Partners 2025 Globale Gesundheitskonferenz in Miami - Gespräch ist für den 11. März um 11:20 Uhr ET angesetzt
- 27. Barclays Globale Gesundheitskonferenz in Miami - Präsentation ist für den 12. März um 14:00 Uhr ET geplant
Das Unternehmen wird bei allen Veranstaltungen Einzelgespräche führen. Webcasts sind auf der Website von MacroGenics im Bereich Investor Relations verfügbar, mit einem Zugriff auf die Wiederholung für 30 Tage.
- None.
- None.
ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March:
- TD Cowen 45th Annual Healthcare Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, March 5, 2025, at 10:30am ET. MacroGenics’ management will also participate in one-on-one meetings.
- Leerink Partners 2025 Global Healthcare Conference (Miami). Dr. Koenig will participate in a fireside chat on Tuesday, March 11, 2025, at 11:20am ET. MacroGenics’ management will also participate in one-on-one meetings.
- Barclays 27th Global Healthcare Conference (Miami). Dr. Koenig will participate in a fireside chat on Wednesday, March 12, 2025, at 2:00pm ET. MacroGenics’ management will also participate in one-on-one meetings.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
FAQ
When is MacroGenics (MGNX) presenting at the TD Cowen Healthcare Conference in March 2025?
How long will the MGNX conference webcasts be available for replay?
Which investor conferences is MacroGenics (MGNX) attending in Miami during March 2025?
Where can investors access MacroGenics' (MGNX) conference presentation webcasts?
What type of meetings will MacroGenics (MGNX) management conduct at these conferences?
